SCHEMBL18860233

SCHEMBL18860233

CC(C)CN1CCC2(CCC2NC(=O)c2ccccc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 4/20 0.45
▸ CARM1 Q86X55 1/20 0.44
▸ PRMT6 Q96LA8 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ MCHR1 Q99705 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ HDAC4 P56524 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ ADRA1D P25100 1/20 0.40
▸ ADRA1A P35348 1/20 0.40
▸ ADRA1B P35368 1/20 0.40
▸ SCN1A P35498 2/20 0.40
▸ SCN5A Q14524 2/20 0.40
▸ SCN9A Q15858 2/20 0.40
▸ ATM Q13315 1/20 0.40
▸ HRH3 Q9Y5N1 1/20 0.40
▸ POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18838432 0.93 CYP2D6 (0.43) CYP2D6CARM1PRMT6NPSR1MEN1
SCHEMBL18838344 0.89 CYP2D6 (0.46) CYP2D6CARM1PRMT6NPSR1MEN1
SCHEMBL18838425 0.84 KCNH2 (0.47) CYP2D6SCN5A
SCHEMBL29361615 0.83 CHRNA7 (0.47) MEN1KMT2AOPRK1
SCHEMBL18838363 0.83 CHRNA7 (0.47) MEN1KMT2AOPRK1
SCHEMBL18860270 0.81 CARM1 (0.48) CARM1PRMT6NPSR1MEN1KMT2A
SCHEMBL18838295 0.81 HTR2A (0.56) CARM1PRMT6MEN1KMT2AHDAC4
SCHEMBL18838336 0.81 HTR2A (0.56) CARM1PRMT6MEN1KMT2AHDAC4
SCHEMBL18838298 0.81 HTR2A (0.56) CARM1PRMT6MEN1KMT2AHDAC4
SCHEMBL18838350 0.80 KMT2A (0.44) CYP2D6CARM1PRMT6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3340988-B1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI INC (US) 2025-04-09 — — EP disclosed
CN-108289886-B Ion channel inhibiting compounds, pharmaceutical formulations and uses 安华赛公司 2022-01-28 — — CN disclosed
US-10562857-B2 Ion channel inhibitory compounds, pharmaceutical formulations, and uses AFASCI, INC. (US) 2020-02-18 — — US disclosed
US-10562857-B2 Ion channel inhibitory compounds, pharmaceutical formulations, and uses AFASCI, INC. (US) 2020-02-18 — — US disclosed
US-20180312471-A1 Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses AFASCI, INC. (US) 2018-11-01 — — US disclosed
WO-2017083867-A1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI, INC. (US) 2017-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562857-B2 Ion channel inhibitory compounds, pharmaceutical formulations, and uses CACNA1I, CACNA1G, CACNA1H CYP2D6 2350/4885CARM1 4614/4885PRMT6 4254/4885
US-20180312471-A1 Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses CACNA1I, CACNA1G, CACNA1H CYP2D6 2350/4885CARM1 4614/4885PRMT6 4254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback